News · TORNTPHARM · 10 Jul 2026 · Amit Lamba

Torrent Pharma Initiates Voluntary Recall for Select Semalix Injection Pens

Torrent Pharmaceuticals Limited announced a precautionary voluntary recall for specific batches of its Semalix injection disposable pens, citing a technical evaluation from its manufacturer.

Lead

Torrent Pharmaceuticals Limited has initiated a voluntary recall for select batches of its Semalix injection disposable pens. This precautionary measure, announced on July 9, 2026, follows a product recall notification issued by Dr. Reddy's Laboratories Ltd. (DRL), the manufacturer of the affected batches, for a technical evaluation. The company emphasized that patient safety remains paramount, stating there is no risk to patients already undergoing treatment with these products due to the recall.

Key highlights

  • Voluntary recall applies to select batches of Semalix injection disposable pens (2 mg and 4 mg).
  • The action is a precautionary measure based on a technical evaluation by manufacturer Dr. Reddy's Laboratories Ltd.
  • Torrent Pharmaceuticals stated there is no risk to patients currently on the treatment.
  • All other Semaglutide SKUs, including oral formulations and other injection strengths/manufacturers, remain unaffected.
  • Unaffected products include Semalix tablets (3 mg, 7 mg, 14 mg), Sembolic tablets (3 mg, 7 mg, 14 mg), Semalix injection (8 mg manufactured by MSN Laboratories), and Sembolic re-usable injection (manufactured by Zydus Lifesciences Ltd.).

What drove it

The recall was prompted by a product recall notification from Dr. Reddy's Laboratories Ltd., the manufacturer of the affected Semalix injection disposable pens. The filing specified that this action was taken as a precautionary measure for a technical evaluation. Torrent Pharmaceuticals Limited did not elaborate further on the specifics of the technical evaluation.

Why it matters

This voluntary recall demonstrates Torrent Pharmaceuticals Limited's responsiveness to product quality concerns originating from its manufacturing partners. By taking swift action in response to the manufacturer's notification, the company aims to uphold product integrity and patient trust. The explicit mention that patient safety is not compromised for those already on treatment, and that the recall is limited to specific batches and manufacturers, helps clarify the scope of the issue.

What to watch

Stakeholders will likely monitor any further updates from Torrent Pharmaceuticals Limited or Dr. Reddy's Laboratories Ltd. regarding the outcome of the technical evaluation or the completion of the recall process. (Source: Exchange filing)

See full P&L, ratios, and valuation on Bull Karma

10-year financials from NSE/BSE exchange filings for TORNTPHARM.

View financial statements

Latest news

Figures sourced from public NSE/BSE exchange filings. Not investment advice. Editorial policy